Boundless Historical Income Statement
| BOLD Stock | USD 2.59 0.07 2.78% |
Historical analysis of Boundless Bio, income statement accounts such as Selling General Administrative of 11.5 M, Other Operating Expenses of 55.2 M or Research Development of 43.6 M can show how well Boundless Bio, Common performed in making a profits. Evaluating Boundless Bio, income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Boundless Bio,'s future profits or losses.
Financial Statement Analysis is much more than just reviewing and examining Boundless Bio, Common latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Boundless Bio, Common is a good buy for the upcoming year.
Boundless |
About Boundless Income Statement Analysis
Boundless Bio, Common Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Boundless Bio, shareholders. The income statement also shows Boundless investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Boundless Bio, Income Statement Chart
Add Fundamental
Depreciation And Amortization
The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.Other Operating Expenses
Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Boundless Bio, Common. It is also known as Boundless Bio, overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.Most accounts from Boundless Bio,'s income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Boundless Bio, Common current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boundless Bio, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. At present, Boundless Bio,'s Research Development is projected to decrease significantly based on the last few years of reporting. The current year's Total Operating Expenses is expected to grow to about 55.2 M, whereas Selling General Administrative is forecasted to decline to about 11.5 M.
| 2010 | 2022 | 2023 | 2024 (projected) | Interest Income | 96K | 668K | 5.3M | 5.5M | Net Interest Income | 96K | 668K | 5.3M | 5.5M |
Boundless Bio, income statement Correlations
Click cells to compare fundamentals
Boundless Bio, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Boundless Bio, income statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Depreciation And Amortization | 3.7M | 7.5M | 682K | 942K | 957K | 909.2K | |
| Selling General Administrative | 17.3M | 30.0M | 6.0M | 9.3M | 12.2M | 11.5M | |
| Other Operating Expenses | 93.2M | 134.4M | 25.3M | 46.5M | 54.8M | 55.2M | |
| Operating Income | (93.2M) | (134.4M) | (25.3M) | (46.5M) | (54.8M) | (57.5M) | |
| Ebit | (92.5M) | (128.8M) | (25.3M) | (46.5M) | (49.4M) | (51.9M) | |
| Research Development | 75.9M | 104.4M | 19.3M | 37.2M | 41.7M | 43.6M | |
| Ebitda | (88.7M) | (121.4M) | (24.6M) | (45.5M) | (48.5M) | (50.9M) | |
| Total Operating Expenses | 93.2M | 134.4M | 25.3M | 46.5M | 54.8M | 55.2M | |
| Income Before Tax | (92.5M) | (128.8M) | (25.2M) | (45.9M) | (49.4M) | (51.9M) | |
| Total Other Income Expense Net | 693K | 5.6M | 91K | 568K | 5.4M | 5.6M | |
| Net Income | (90.2M) | (128.8M) | (25.2M) | (45.9M) | (49.4M) | (51.9M) | |
| Income Tax Expense | (2.2M) | 5.6M | (96K) | (668K) | (5.3M) | (5.0M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Boundless Bio, Common is a strong investment it is important to analyze Boundless Bio,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Boundless Bio,'s future performance. For an informed investment choice regarding Boundless Stock, refer to the following important reports:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Boundless Bio, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Boundless Bio,. If investors know Boundless will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Boundless Bio, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.59) | Return On Assets (0.24) | Return On Equity (0.36) |
The market value of Boundless Bio, Common is measured differently than its book value, which is the value of Boundless that is recorded on the company's balance sheet. Investors also form their own opinion of Boundless Bio,'s value that differs from its market value or its book value, called intrinsic value, which is Boundless Bio,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Boundless Bio,'s market value can be influenced by many factors that don't directly affect Boundless Bio,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Boundless Bio,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Boundless Bio, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Boundless Bio,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.